Scynexis Inc
$ 5.24
0.77%
07 Aug - close price
- Market Cap 52,035,000 USD
- Current Price $ 5.24
- High / Low $ 5.52 / 5.21
- Stock P/E N/A
- Book Value 5.33
- EPS -3.85
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.53 %
- 52 Week High 10.48
- 52 Week Low 3.53
About
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Analyst Target Price
$33.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-04 | 2025-11-05 | 2025-08-14 | 2025-05-16 | 2025-03-12 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-29 | 2023-11-12 | 2023-08-13 |
| Reported EPS | -3.36 | 2 | -0.17 | -1.12 | -0.17 | -0.09 | -0.48 | -2.4 | 0.08 | -0.39 | -0.32 | 19.68 |
| Estimated EPS | -0.99 | 1.0133 | -0.21 | -1.52 | -0.23 | -0.22 | -0.78 | -1.62 | -1.55 | -0.2 | -1.17 | 11.62 |
| Surprise | -2.37 | 0.9867 | 0.04 | 0.4 | 0.06 | 0.13 | 0.3 | -0.78 | 1.63 | -0.19 | 0.85 | 8.06 |
| Surprise Percentage | -239.3939% | 97.3749% | 19.0476% | 26.3158% | 26.087% | 59.0909% | 38.4615% | -48.1481% | 105.1613% | -95% | 72.6496% | 69.3632% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCYX
2026-07-31 17:09:56
This article identifies 12 healthcare stocks that experienced significant movement during Friday's intraday trading session. It highlights both gainers, such as Replimune Group and SCYNEXIS, which saw substantial increases, and losers like Karyopharm Therapeutics and Nuwellis, which experienced notable declines. The report provides specific percentage changes and market capitalization for each mentioned company.
2026-07-31 17:09:22
The article provides a financial health analysis of SCYNEXIS Inc (SCYX), reporting its current financial score as 9.29, ranking 3 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust with high operating efficiency, despite a significant year-over-year decrease in revenue and net profit. The analysis also touches on various financial dimensions like quality of earnings, operational efficiency, growth potential, and shareholder returns, noting that relevant data for several of these metrics have not been disclosed by the company yet.
2026-07-31 04:09:56
The article provides a valuation analysis for SCYNEXIS Inc (SCYX), noting its current valuation score of 9.32, ranking 21st in the Pharmaceuticals industry. It highlights the company's current P/E ratio of -10.06, which is significantly below its recent high. The article also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-30 10:14:41
This article provides a risk assessment for SCYNEXIS Inc (SCYX), ranking it 104 out of 155 in the Pharmaceuticals industry with a score of 3.19. Key metrics such as beta, VaR, maximum drawdown, volatility, and Sharpe Ratio are presented to detail the stock's performance and risk profile. The report notes the stock's tendency to outperform during upward markets and decline more significantly in downward markets due to its beta of 1.07.
2026-07-29 15:14:41
SCYNEXIS Inc. (SCYX) shows strong fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as a "Buy" with a significant upside potential of 839.68%. The company is pioneering medicine for difficult-to-treat infections, with its antifungal platform fungerps, and its drug BREXAFEMME approved by the FDA.
2026-07-28 04:18:29
This article provides a detailed balance sheet for SCYNEXIS Inc (SCYX), allowing users to evaluate the company's financial health, fundamentals, and key ratios. It includes quarterly and annual data for various assets, liabilities, and shareholders' equity items. The article also provides answers to frequently asked questions regarding SCYX's financial metrics, cash, total liabilities, total assets, and shareholders' equity.
